Indirect data suggest oral semaglutide outperforms orforglipron on weight loss and tolerability, with patients also favoring its treatment profile.

Richard Jaenisch and Christopher Cole discuss AI in pharma manufacturing, covering learning steps, output evaluation, hallucinations, and FDA/EMA guiding principles.

PRAC-triggered post-authorization actions for cenobamate will cascade across SmPC, PIL, and controlled regulatory materials, ...

Laboratory testing validates low migration, low odor, and low VOC in clean, sustainable secondary packaging. Even paperboard ...

As a part of PDA Week 2026, Christopher Lewis, Emoja Biopharma and President of the Mountain States PDA Chapter, sat down ...

Legacy web forms used for clinical trial recruitment, adverse event reporting, laboratory data collection, and regulatory ...

This week, PharmTech took a look at the shift toward proactive, data-driven contamination control, the adoption of advanced material science to solve manufacturing hurdles, and an ...

Lilly licenses Insilico's AI drug discovery platform in a deal worth up to $2.75B, signaling a shift in how novel ...

VP of operations and support at Kiteworks, with more than 20 years of experience in IT support and services. Since joining ...

Digital twins function as synchronized, real-time operational mirrors, where divergence from the physical process triggers ...